TIAGO KENJI TAKAHASHI
Índice h a partir de 2011
6
Projetos de Pesquisa
Unidades Organizacionais
Instituto do Câncer do Estado de São Paulo, Hospital das Clínicas, Faculdade de Medicina
41 resultados
Resultados de Busca
Agora exibindo 1 - 10 de 41
conferenceObject Role of paclitaxel and platinum-based chemotherapy in locally advanced and metastatic penile squamous cell carcinoma.(2014) BARROSO-SOUSA, Romualdo; GUINDALINI, Rodrigo Santa Cruz; NEGRAO, Marcelo Vallati; NAKAZATO, Denyel; MONLZ, Camila Matta Venchlaruttl; TAKAHASHI, Tlago Kenji; DZIK, Carlos- Multiagent chemotherapy for metastatic adenocarcinoma of the seminal vesicle(2014) GUINDALINI, Rodrigo S. C.; MAK, Milena P.; TAKAHASHI, Tiago K.; TESTA, Laura; DZIK, CarlosAdenocarcinoma of the seminal vesicle is a rare condition, with fewer than 60 cases described in the literature. Most reports highlight the histopathological characteristics of the tumor; however, the role of chemotherapy, especially in the metastatic setting, is poorly described. In this paper, we describe a patient with metastatic disease, who sustained a response to modified FOLFOX6 as first-line therapy. This platinum-based combination therapy seems effective in this scenario and may provide an opportunity for extended survival and relief of symptoms. (C) 2013 Wolters Kluwer Health vertical bar Lippincott Williams & Wilkins.
conferenceObject Characterization of EGFR Activating Mutations in Brazilian Patients with Pulmonary Adenocarcinoma(2015) YEN, Cheng T.; BITTON, Rafael C.; LIMA, Luiz G. C. A. De; AMADIO, Alex V.; TAKAHASHI, Tiago K.; MARINI, Andrea M.; TAKAGAKI, Tereza Y.; TERRA, Ricardo M.; MELLO, Evandro S.; CASTRO JR., Gilberto DebookPart Princípios do tratamento oncológico(2017) BRAGA, Henrique Faria; MAK, Milena Perez; TAKAHASHI, Tiago KenjiconferenceObject Long term toxicities after cisplatin-based concurrent chemoradiation in head & neck squamous cell carcinoma (HNSCC) disease-free patients: A cross-sectional study(2015) RIVELLI, T. G.; SIMAO, E. F.; MAK, M. P.; MARTINS, R. Eiras; TAKAHASHI, T. K.; MARINI, A. M.; ROITBERG, F. S. R.; MESQUITA, C.; KULCSAR, M. A. V.; CASTRO JR., G.bookPart Inibidores de tirosina-quinase(2013) TAKAHASHI, Tiago Kenji; MAK, Milena Perez; FERRARI, Anezka Carvalho Rubin de Celis; HOFF, Paulo Marcelo GehmbookPart Neoplasia de sítio primário indeterminado(2017) MAK, Milena Perez; TAKAHASHI, Tiago Kenji; SARAGIOTTO, Daniel FernandesbookPart Princípios do tratamento oncológico(2015) TAKAHASHI, Tiago Kenji; MAK, Milena PerezbookPart Neoplasias de sítio primário indeterminado(2015) MAK, Milena Perez; TAKAHASHI, Tiago Kenji; SARAGIOTTO, Daniel FernandesconferenceObject ERCC1 AND BETA-TUBULIN III IN ADVANCED NSCLC PATIENTS TREATED WITH CISPLATIN-VINORELBINE(2012) CASTRO JR., G. de; VICTOR, C. R.; BIGATON, F. J.; TAKAHASHI, T. K.; FEHER, O.; SABER, A. M. Ab'; TAKAGAKI, T. Y.; SIQUEIRA, S. A. C.; CHAMMAS, R.; HOFF, P. M. G.Background: Platinum-containing chemotherapy remains as the standard treatment in advanced/metastatic non-small-cell lung cancer (NSC LC) patients (pts). Increased ERCC 1 expression has been associated with resistance to platinum-based therapies, and beta-tubulin III (TUBB 3) was shown to be involved in resistance to antimicrotubule agents. Here we studied these tumor markers in NSC LC pts treated with cisplatin-vinorelbine and correlated their expression with survival. Methods: It is a retrospective study on pts diagnosed with advanced/metastatic NSC LC (TNM 6th ed), consecutively identified. All pts were treated with cisplatin 80 mg/m2 d1 and vinorelbine 30 mg/m2 d1, d8, d15, every 21 days, 4–6 cycles, in our Institution, between Sep/2002 and Oct/2008. ERCC 1 (clone 8F1) and TUBB 3 (clone TUJ1) expression were evaluated by immunohistochemistry, and biomarker expression was considered as high when more than 10% of tumor cells presented moderate to strong staining, nuclear or cytoplasmic, respectively. Overall survival (OS) was estimated by the Kaplan-Meier method and curves were compared with log-rank. Results: 142 pts were studied; median age 63 y (34-87), 67% male and 86% current smokers. Adenocarcinoma (ADC, 58 pts, 43%), followed by squamous cell carcinoma (SCC , 50 pts, 37%) were the most frequent histologic types. 100 pts (71%) were staged as IV and 34 pts (24%) as IIIB. The median number of cycles was 4 (1-7). Median OS was 7.9 mo. Overall, high ERCC 1 expression was observed in 61/104 pts (59%) and high TUBB 3 expression in 55/109 pts (51%). According to histologic types, low ERCC 1 expression was observed in 7/42 SCC pts (16%) and in 35/63 ADC pts (56%) (p=0.0004). Among ADC pts, 1-y OS rate was 28% and 47% in pts which tumors presented with high and low ERCC 1 expression, respectively (HR 1.57, 95% CI 0.9-2.7, p=0.08). TUBB 3 expression neither presented any difference between SCC and ADC types, nor any prognostic impact in terms of OS. Conclusions: Low ERCC 1 expression was observed more frequently in pts with advanced lung ADC and it was a favorable prognostic factor in ADC pts treated with cisplatin-vinorelbine.